Despite greater chronic pain prevalence in females compared with males, and the analgesic potential of cannabinoid receptor type 2 (CB2) agonists, CB2 agonists have rarely been tested in females. The aim of the present study was to compare the antinociceptive effects of a CB2-preferring agonist, (2-methyl-1-propyl-1H-indol-3-yl)-1-naphthalenylmethanone (JWH015), in female and male rats against acute pain and persistent inflammatory pain. JWH015 (5-20 mg/kg, intraperitoneally) produced dosedependent and time-dependent increases in latency to respond on the tail withdrawal and paw pressure tests that did not differ statistically between the sexes. JWH015 dosedependently decreased locomotor activity in both sexes, but was more potent in females than males. JWH015 produced little catalepsy in either sex. In females, the antinociceptive effects of JWH015 against acute pain were blocked by rimonabant and SR144528, whereas locomotor suppression was antagonized by rimonabant. When administered 3 days after intraplantar injection of complete Freund's adjuvant, JWH015 produced a significantly greater antiallodynic effect in females at the highest dose tested (10 mg/kg, intraperitoneally). Antiallodynic effects of JWH015 were antagonized by rimonabant and SR144528 in both sexes. These studies indicate that systemically administered JWH015 produced antinociception that was both CB1 and CB2 receptor-mediated in both sexes. Unlike Δ-9-tetrahydrocannabinol and other nonselective cannabinoid agonists, the CB2-preferring agonist JWH015 may produce more equivalent antinociception in females and males.
Introduction
Cannabinoid drugs may provide a useful alternative to opioids for the treatment of chronic pain. Clinical trials testing various cannabinoids indicate that they significantly reduce chronic pain associated with multiple sclerosis, fibromyalgia, diabetic or other neuropathy, and rheumatoid arthritis (for reviews see Lynch and Campbell, 2011; Lynch and Ware, 2015) . Adverse effects are reported to be relatively mild and well-tolerated, and some studies also report improvements in sleep (Lynch and Ware, 2015) . Thus, cannabinoids may be relatively safe for long-term use to alleviate chronic pain .
One drawback to the use of cannabinoids for treating chronic pain is their central nervous system side effects, including psychoactive effects. However, psychoactive effects such as reinforcing/rewarding effects of cannabinoids appear to be mediated exclusively by the cannabinoid 1 (CB1) receptor (Braida et al., 2004; Zangen et al., 2006) . For this reason, it has been suggested that cannabinoids acting at cannabinoid 2 (CB2) receptors may be preferable for long-term use as pain therapeutics (Malan et al., 2003; Guindon and Hohmann, 2008) . In animal studies, both CB1 and CB2 receptors have been shown to mediate the antinociceptive effects of a range of cannabinoids; however, CB2 receptors appear to be more involved in cannabinoid antinociception against chronic than acute pain, perhaps because CB2 receptors are upregulated during inflammation and nerve injury (Zhang et al., 2003; Hsieh et al., 2011) .
In the present study, we examined the effects of (2-methyl-1-propyl-1H-indol-3-yl)-1-naphthalenylmethanone (JWH015) in acute pain tests and in a persistent inflammatory pain model. JWH015 binds to both CB1 and CB2 receptors, but has~10-30 times greater affinity for CB2 than CB1 receptors, compared with the~1 : 1 CB1 : CB2 binding ratio for Δ-9-tetrahydrocannabinol (THC) (Huffman et al., 2005; Pertwee, 2008) . JWH015 administered i.t., has been shown to decrease mechanical allodynia and/or thermal hyperalgesia that developed after hindpaw incision (Romero-Sandoval and Eisenach, 2007; Landry et al., 2012) or peripheral nerve injury (Romero-Sandoval et al., 2008) in male rats, and after bone cancer induction in male mice (Gu et al., 2011) . To our knowledge, JWH015 has not been tested in females of any species. Given the greater prevalence of chronic pain in women compared with men (Unruh, 1996) , it is important to characterize the therapeutic potential of CB2 agonists in both sexes.
Sex differences in the antinociceptive potency of nonselective cannabinoids have been observed. For example, THC and CP55940 were more potent in female rats compared with males against acute thermal and/or mechanical pain (Tseng and Craft, 2001; Romero et al., 2002; Craft et al., 2012) and against persistent inflammatory pain (Craft et al., 2013) . Thus, both females and males were tested in the present study, and we hypothesized that JWH015 would be more potent in females than in males. A previous study demonstrated that JWH015-induced antinociception was blocked by a CB2-receptor-selective but not by a CB1 receptorselective antagonist in male rats (Romero-Sandoval and Eisenach, 2007) , so we expected that JWH015-induced antinociception would be CB2 receptor-mediated in both sexes.
Methods

Subjects
Adult Sprague-Dawley rats were bred in-house from Harlan stock (Livermore, California, USA). They were 60-89 days old on the first day of testing (body weight: 184-272 g females, 239-431 g males). Rats were housed under a 12 : 12 h light : dark cycle (lights on at 06:00 h) in a room maintained at 21 2°C, with TekFresh bedding (Envigo, Denver, Colorado, USA), with typically two samesex rats/cage. Males and females were housed in the same room, but on different racks that were~1.5 m apart, and rats had free access to food and water except during testing. Rats were randomly assigned to treatment groups with the exception that care was taken to avoid assigning same-sex siblings to the same treatment group. Rats were tested during the light part of the cycle, typically between 09:00 and 15:00 h, and were treated in accordance with the National Research Council (2011) guidelines.
Apparatus
Tail withdrawal antinociception was assessed using a 2.5 l water bath (Precision Scientifics Inc., Winchester, Virginia, USA) set to 50 0.5°C; latency to withdraw the tail was timed with a hand-held stopwatch to the nearest 0.01 s. Paw pressure antinociception was assessed using an analgesy-meter (Ugo-Basile, Varese, Italy). The pressure on the paw began at 30 g and increased at a constant rate of 48 g/s to a maximum of 750 g (15 s). Horizontal locomotor activity was measured using a photobeam apparatus (Opto-varimex; Columbus Instruments, Columbus, Ohio, USA), in which 15 photobeams cross the width of a 20 × 40 × 23 cm 3 transparent rodent cage, with photobeams spaced 2.5 cm apart and 8 cm above the cage floor. Catalepsy was measured using a bar test (ring stand with a 1.5-cm diameter horizontal bar); time spent on the bar was measured with a hand-held stopwatch. An electronic von Frey anesthesiometer (IITC Life Science, Woodland Hills, Caliofrnia, USA) was used to measure mechanical allodynia. To measure thermal hyperalgesia, a plantar (Hargreaves) apparatus (Ugo-Basile) was used. Tests were conducted on both the left and right hindpaws; half of the rats in each treatment group were tested on the left hindpaw first and the other half were tested on the right hindpaw first. An incapacitance meter (Stoelting, Wood Dale, Illinois, USA) was used to record weight placed on each hindpaw in grams. Calipers were used to assess (in mm) maximal dorsal-ventral hindpaw thickness, a measure of edema.
Behavioral procedures
Study 1: JWH015 effects on acute pain and motor behaviors Baseline nociception was assessed by testing each rat twice on the tail withdrawal and paw pressure tests, in that order. Thirty minutes later, vehicle or a single dose of JWH015 (5, 10, or 20 mg/kg) was injected intraperitoneally (i.p.) (experimenter blinded to dose). Rats were then tested on tail withdrawal and paw pressure tests at 15, 30, 60, and 120 min after injection. For the tail withdrawal test, the distal 5 cm of the tail was submerged in the warm water bath and latency to withdraw the tail was recorded; if the rat did not respond by the 12-s cutoff, the test was terminated and 12 s was recorded. For the paw pressure test, latency to withdraw or attempt to withdraw the hindpaw was recorded; if the rat did not respond by the 15-s cutoff, the test was terminated and 15 s was recorded. Horizontal locomotor activity was measured as the number of photobeams broken in a 5-min period, beginning immediately after nociceptive testing at 30, 60, and 120 min after injection. Catalepsy was assessed immediately after the locomotor test at the 60-min time point only, on the basis of a previous study demonstrating significant antinociceptive effects of JWH015 at 60 min after its injection in male rats (Landry et al., 2012) . Latency to withdraw both paws from the bar or jump up on the bar was recorded; if the rat did not respond by 12 s, the test was terminated and 12 s was recorded. Rats were returned to their home cages between testing periods.
In a separate experiment, cannabinoid receptor mediation of the effects of JWH015 on acute pain and motor behaviors was examined in females only. After baseline testing as described above, vehicle or a single dose of rimonabant (0.1 mg/kg) or SR144528 (3.2 mg/kg) was injected i.p.; these antagonist doses were the lowest effective doses in a previous study of cannabinoid receptor mediation of THC's acute antinociceptive effects in female rats (Craft et al., 2012) . Thirty minutes later, vehicle or a single dose of JWH015 (5, 10, 20, or 40 mg/kg) was injected i.p., and rats were tested as described above.
Study 2: JWH015 effects on persistent inflammatory pain Persistent paw inflammation and pain were induced with a 0.1-ml intraplantar (i.pl.) injection of a 1 mg/ml complete Freund's adjuvant (CFA) solution (killed Mycobacterium butyricum suspended in mineral oil; Sigma-Aldrich, St. Louis, Missouri, USA). On day 0 (before CFA injection), rats were habituated to hanging wire cages for 15 min. Baseline sensitivity was determined by the von Frey test (force applied to induce hindpaw withdrawal, in g), the Hargreaves test (latency to withdraw the hindpaw from a heat stimulus, in s), and the incapacitance test (weight born on left vs. right hindpaws). Three measurements were taken per hindpaw on each of the tests, with~30 s between trials. Maximal dorsal-ventral hindpaw thickness was measured. After baseline testing was completed, rats were briefly anesthetized with isoflurane, and CFA was injected into the right plantar hindpaw. Three days after CFA treatment, rats were injected i.p. with vehicle, 5, or 10 mg/kg JWH015 (experimenter blinded to dose), and placed into hanging wire cages for a 15-min habituation period. Then rats were assessed on the von Frey, Hargreaves, and incapacitance tests at 15, 30, 60, 120, 180, and 240 min after injection. Given that no significant catalepsy was observed 60 min after JWH015 injection, and peak antinociception was observed at 15-30 min after injection in study 1, in study 2 catalepsy was assessed at 15 and 30 min after injection. Paw thickness was measured 60, 120, and 240 min after vehicle or JWH015 injection. Rats were returned to their home cages between testing periods.
To determine receptor mediation of the effects of JWH015 in the CFA model, a separate experiment was conducted. An i.pl. CFA injection was administered to the right hindpaw while rats were under brief isoflurane anesthesia. Three days after CFA injection, vehicle or antagonist (rimonabant or SR144528, 1.0 mg/kg) was injected i.p., then 30 min later vehicle or 10 mg/kg JWH015 was administered i.p. (experimenter blinded to antagonist condition). Antagonist doses were chosen on the basis of a previous study examining receptor mediation of the effects of THC in the CFA model in female and male rats (Craft et al., 2013) . Mechanical allodynia was measured as described above, at 30, 60, and 120 min after injection.
Drugs
Rimonabant (SR141716A) and SR144528 (National Institute on Drug Abuse, Bethesda, Maryland, USA) were dissolved in a 1 : 1 : 18 (ethanol : cremaphor : saline) solution, which served as the vehicle. In cellular assays, these antagonists demonstrate binding selectivity for CB1 (rimonabant) or CB2 (SR144528) receptors, although they may act as inverse agonists at high concentrations (Govaerts et al., 2004) . In male rats, rimonabant doses as low as 0.32-1 mg/kg i.p. antagonize THC's antinociceptive and motoric effects, whereas SR144528 doses as high as 10 mg/kg i.p. do not (Craft et al., 2012) . JWH015 was purchased from Cayman Chemical (Ann Arbor, Michigan, USA); it was dissolved in DMSO to which distilled water was added for a final DMSO concentration of 75%. All drugs were administered i.p. in volumes of 1-2 ml/kg.
Data analysis Study 1
Baseline nociceptive latencies for each rat on the tail withdrawal and paw pressure tests were calculated as the mean of the two preinjection trials. To adjust for individual differences in baseline latency to respond, response latencies following drug administration were converted to % maximum possible effect (% MPE) in each rat: [(drug latency − mean baseline latency)/(cutoff latency − mean baseline latency)] × 100%. Because female rats tend to locomote more than males (Craft, 2008) , locomotor activity in drug-treated rats (number of photobeam breaks) at each time point was converted to % control activity in the same-sex vehicle control group, at each time point: (number of photobeam breaks in drug-treated rat/mean number of photobeam breaks in same-sex vehicle control group) × 100%. Catalepsy scores were dropped before analysis if the rat was noted to be moving its paws and/or displaying continuous sniffing/head movement along the bar during the test. On the basis of this criterion, the catalepsy score of one rat (a vehicletreated female) was dropped.
Time course data (% MPE tail withdrawal and paw pressure scores, and % control locomotor scores for individual rats) were analyzed using analysis of variance (ANOVA), with factors of sex (two levels), JWH015 dose (three to four levels), and time (three to four levels, repeated). Catalepsy data (time spent on bar, in s) were analyzed using ANOVA, with factors of sex (two levels) and JWH015 dose (four levels). In the first experiment, Dunnett's post-hoc test was used to compare each dose to vehicle; t-tests with a Bonferroni correction were used for other post-hoc comparisons (e.g. sex differences at single time points). The effects of JWH015 in vehiclepretreated rats were compared with that of antagonistpretreated rats by ANOVA, with factors of antagonist (three levels: vehicle, rimonabant, SR144528) and JWH015 dose (two levels: 10 and 20 mg/kg). Tukey's post-hoc test was used to compare each antagonist with vehicle. Significance was set at P less than or equal to 0.05 for all statistical tests. Greenhouse-Geisser-adjusted F, d.f., and P values are only noted when the assumption of homogeneous variance was not met and the adjusted P value was greater than 0.05 (i.e. if the adjusted P value was still ≤ 0.05, the unadjusted F, d.f., and P values are reported).
Study 2
At baseline and at each time point after drug injection, the mean of the three trials was calculated for each paw of each rat on the von Frey, Hargreaves, and weight-bearing tests. A mean of the two catalepsy scores (taken at 15 and 30 min after injection) was calculated for each rat, except in cases when the rat was noted to be moving its paws and/or displaying continuous sniffing/head movement along the bar during a test, in cases where that catalepsy score was dropped. On the basis of this criterion, two rats (both females: one vehicle-treated, one treated with 10 mg/kg JWH015) had no usable catalepsy scores, therefore, they were not included in the analysis; five other rats had one usable catalepsy score (two males treated with 5 mg/kg JWH015, two vehicle-treated females and one female treated with 5 mg/kg JWH015). For the von Frey and Hargreaves tests, baseline data were compared between males and females, and given the significant sex differences on all measures, vehicle and drug data for the right hindpaw were transformed to % of the rat's own baseline score at each time point, before analysis of drug effects on the von Frey, Hargreaves, and weight-bearing tests. For example, for the von Frey test, % of baseline = [mechanical threshold in right hindpaw after drug injection (g)/baseline mechanical threshold in right hindpaw (g)] × 100%. Paw thickness was converted to % of baseline paw thickness (baseline = 3 days after CFA, but before JWH015 injection), for each rat at each time point. The time course of drug effects on the von Frey, Hargreaves, weightbearing, and paw thickness tests was then analyzed by ANOVA, with variables: sex (two levels), JWH015 dose (three levels), and time (three to six levels, repeated). Because there were no interactions of sex with time, area under the curve (AUC) values are then calculated using the trapezoidal rule, to summarize the time course data for the von Frey, Hargreaves, and weight-bearing tests. AUC data are shown graphically, and were analyzed by ANOVA with sex (two levels) and JWH015 dose (three levels) variables. No reduction in paw thickness was observed until the 120-min time point (and the 120-min data were not significantly different from 240-min data); thus, the mean of values at 120 and 240 min after injection were calculated for each rat, and these means were analyzed by ANOVA, with sex (two levels) and JWH015 dose (two levels) variables.
For the antagonism experiment, AUC values were analyzed by ANOVA, with antagonist (vehicle, rimonabant, SR144528), JWH015 dose (two levels), and sex (two levels) variables.
Results
Study 1: JWH015 effects on acute pain and motor activity Figure 1 shows the time course of antinociceptive effects of JWH015 on the tail withdrawal and paw pressure tests. JWH015 produced dose-dependent and time-dependent increases in latency to respond on the tail withdrawal test in females and males, with peak effects at 15-30 min that declined to baseline by 60-120 min after injection [JWH015 dose × time: F(9,189) = 4.18, P < 0.001; Fig. 1a and c]. In females, JWH015 produced time-dependent increases in latency to respond (JWH015 dose × time: F(9,96) = 4.37, P < 0.001); post-hoc tests indicated that these increases were significant at 20 mg/kg (P = 0.014), but not at 10 mg/kg (P = 0.055) or at 5 mg/kg. In males, JWH015 produced significant increases in latency to respond (JWH015 dose: F(1,31) = 5.14, P < 0.005); posthoc tests indicated that these increases were significant at 5 mg/kg (P = 0.021) and 20 mg/kg (P = 0.004), but not at 10 mg/kg. Although the highest dose of JWH015 tested, 20 mg/kg, produced a greater peak effect in females compared with males, there were no significant sex differences in JWH015 effect. On the paw pressure test (Fig. 1b and d) , JWH015 also produced dose-dependent increases in latency to respond [JWH015 dose: F(3,63) = 10.77, P < 0.001] that was not statistically different between females and males. In females, JWH015 produced significant increases in latency to respond [F(3,32) = 7.97, P < 0.001]; post-hoc tests indicated that these increases were significant at 20 mg/kg only (P < 0.001). In males, JWH015 produced significant increases in latency to respond [F(3,31) = 4.04, P < 0.02]; post-hoc tests indicated that these increases were significant at 20 mg/kg only (P = 0.025). Figure 2 shows the motoric effects of JWH015, as measured on locomotor activity and catalepsy tests. Figure 2a shows that JWH015 dose-dependently decreased horizontal locomotion in both sexes; however, drug effects were greater in females than males at some doses and time points [sex × JWH015 dose × time: F(4,98) = 2.87, P < 0.05]. Specifically, whereas 5 mg/kg decreased locomotion in females at 30-60 min after injection, this dose increased or did not alter locomotion in males [sex × time: F(2,28) = 5.69, P < 0.01]. The 10 mg/kg dose of JWH015 decreased locomotion more in females than in males at early time points [sex × time: F(2,34) = 7.13, P < 0.005], whereas the highest dose tested, 20 mg/kg, decreased locomotion in both sexes with no statistically significant differences. In contrast to the dose-dependent decreases in behavior on the locomotor activity test, JWH015 produced no significant catalepsy at any dose, in either sex [JWH015 dose: F(3,63) = 1.79, NS; Fig. 2b ]. Figure 3 shows antagonism of JWH015 by rimonabant and SR144528 at peak times of JWH015 effect (15 min after injection for paw pressure and tail withdrawal and 30 min after injection for locomotor activity). This experiment was conducted in female rats only. On the tail withdrawal and paw pressure tests, the JWH015 dose-effect curve was shifted to the right or flattened by both rimonabant and SR144528. A statistical comparison of the effects produced by 10-20 mg/kg JWH015 between the vehicle-pretreated and antagonist-pretreated groups confirmed that both antagonists significantly reduced JWH015 effects, on the tail withdrawal test [antagonist: F(2,28) = 6.69, P < 0.005; rimonabant vs. vehicle: P < 0.001; SR144528 vs. vehicle: P < 0.01] and on the paw pressure test [antagonist: F(2,28) = 4.12, P < 0.05; rimonabant vs. vehicle, P < 0.053; SR144528 vs. vehicle, P = 0.05]. Rimonabant also antagonized JWH015-induced decreases in locomotor activity, whereas the SR144528-induced rightward shift in the JWH015 dose-effect curve was minimal (Fig. 3b) . A statistical comparison of the effect of 10-20 mg/kg JWH015 between the vehicle-pretreated and antagonist-pretreated groups confirmed that only rimonabant significantly blocked JWH015-induced decreases in locomotor activity [antagonist: F(2,28) = 6.91, P < 0.005; rimonabant vs. vehicle, P = 0.002; SR144528 vs. vehicle, P = 0.27]. Copyright r 2018 Wolters Kluwer Health, Inc. All rights reserved.
Study 2: JWH015 effects on persistent inflammatory pain
There were no sex differences in the time course of JWH015 effect on any nociceptive test in study 2 (no significant sex × time or sex × dose × time interactions; so drug effects are summarized as AUC values. Figure 4a shows that i.pl. CFA injection decreased mechanical threshold (von Frey test) similarly in both sexes; that is, there was a significant difference in mechanical threshold between the left, non-CFA-injected paw and the right, CFA-injected paw in vehicle-treated rats (compare first pair vs. second pair of bars over '0') [paw: F(1,18) = 129.00, P < 0.001]. When administered 3 days after i.pl. CFA, JWH015 produced dose-dependent increases in mechanical threshold in both sexes [dose: F(2,54) = 29.06, P < 0.001], with greater effects in females compared with males [sex: F(1,54) = 11.63, P < 0.001; Fig. 4a ]. Further analysis at each dose showed that males and females differed significantly only at the highest dose tested, 10 mg/kg (P = 0.025). Figure 4b shows that i.pl. CFA injection also shortened latency to respond to noxious heat (Hargreaves test) similarly in both sexes; that is, heat sensitivity was significantly greater in the right, CFA-injected paw than in the left, non-CFA-injected paw (compare first pair vs. second pair of bars over '0') [paw: F(1,18) = 32.97, P < 0.001]. JWH015 dose-dependently attenuated CFAinduced heat hypersensitivity, with no sex difference [dose: F(2,54) = 16.77, P < 0.001]. Figure 4c shows that i.pl. CFA injection also decreased weight-bearing on the CFA-injected paw compared to the non-CFA-injected paw in both sexes (compare first pair vs. second pair of bars over '0') [paw: F(1,18) = 60.60, P < 0.001]. JWH015 slightly increased weight-bearing on the CFA-injected hindpaw in both sexes, but this effect was not statistically significant [dose: F(2,54) = 1.34, NS; Fig. 4 ]. Maximal effects on this test were 25-30% MPE at the time of peak effect. Dose-effect curves for intraperitoneal (i.p.) JWH015 alone and in combination with the CB1 antagonist rimonabant (0.1 mg/kg i.p.) or the CB2 antagonist SR144528 (3.2 mg/kg i.p.), on two acute pain tests (a, b), and locomotor activity (c), in female rats. Curves were constructed from time course data, using data at 15 min after injection (paw pressure and tail withdrawal) or 30 min after injection (locomotor activity). Each point is the mean SEM of 5-7 rats. Craft et al. 285 CFA injection also increased paw thickness, an index of edema. The average increase in paw thickness from before to 3 days after CFA injection was~0.63 to 1.12 mm in vehicle-treated males, and 0.54 to 1.0 mm in vehicletreated females. Figure 4d shows that JWH015 significantly decreased paw thickness in the CFA-injected paw [dose: F(2,54) = 14.43, P < 0.001]. There was no significant main effect of sex or sex by dose interaction on paw thickness. Analysis of the JWH015 effect within sex showed a significant effect in females [F(2,27) = 35.36, P < 0.001], but not males [F(2,27) = 3.09, P = 0.062].
JWH015 antinociception
In this experiment, catalepsy was measured at 15 and 30 min instead of 60 min after injection, to try to capture peak JWH015 effects on catalepsy; at these earlier time points JWH015 produced some catalepsy, but with no significant sex difference [dose: F(2,52) = 4.85, P < 0.02; data not shown]. For example, mean time spent on the bar was 4.1 0.6 versus 5.5 1.1 s in females versus males, respectively, at 10 mg/kg.
To determine CB1 and CB2 receptor mediation of JWH015 effect against persistent inflammatory pain, a separate experiment was conducted in which vehicle, rimonabant, or SR144528 was administered 30 min before vehicle or 10 mg/kg JWH015. Figure 5 shows that the antiallodynic effect of JWH015 was antagonized by both rimonabant and SR144528, with no sex difference [antagonist × JWH015: F(2,107) = 6.76; P < 0.002].
Discussion
This study demonstrates that when administered systemically, the putative CB2-preferring agonist JWH015 produces antinociception in both female and male rats on tests of acute heat and pressure pain. Furthermore, in a model of persistent inflammatory pain, JWH015 attenuates mechanical allodynia, heat hyperalgesia, and edema. However, the antinociceptive effects of JWH015 were mediated not only by CB2 receptors, but also by CB1 receptors, as indicated by antagonism by both rimonabant and SR144528 on the tail withdrawal and paw pressure tests (study 1, females), and on the von Frey test (study 2, females and males). JWH015 also dose-dependently decreased locomotor activity, but produced no significant catalepsy at doses that produced antinociception. JWH015 produced similar antinociception in females and males, but greater locomotor suppression in females.
The results of the present study agree with those of previous studies demonstrating that CB2-preferring agonists can produce antinociception, extending these findings to females. For example, when administered systemically to male mice, the CB2-preferring agonist AM1241 produced dose-dependent antinociception on hotplate and tail immersion tests (Ibrahim et al., 2006) , and another CB2-preferring agonist, JWH133, decreased formalininduced (phase I) pain-related behavior (Jafari et al., 2007) . i.t., administered JWH015 decreased mechanical allodynia and/or thermal hyperalgesia that developed after hindpaw incision (Romero-Sandoval and Eisenach, 2007; Landry et al., 2012) or peripheral nerve injury (Romero-Sandoval et al., 2008) in male rats, and after bone cancer induction in male mice (Gu et al., 2011) . Several of these studies confirmed CB2 receptor involvement in JWH015-induced antinociception by AM630 antagonism, but only one study ruled out CB1 receptor involvement (no antagonism by AM281: Romero-Sandoval and Eisenach, 2007) . Surprisingly, in the present study both CB2 and CB1 receptor-selective antagonists blocked JWH015-induced antinociception. JWH015 has been estimated to have 10-30 times greater affinity for CB2 than CB1 receptors (Huffman et al., 2005; Pertwee, 2008) , and there is little previous evidence that it acts at CB1 receptors. The only study we could find showed that the electrophysiological effects of JWH015 in mouse hippocampal neurons were CB1 receptor-mediated (Murataeva et al., 2012) . The CB1 receptor-mediated antinociceptive effects of JWH015 observed in the present study could be because of the fact that we administered the drug systemically rather than intrathecally (i.t.), the route used in most previous studies examining receptor mediation of JWH015-induced antinociception (Gu et al., 2011; Landry et al., 2012; Romero-Sandoval et al., 2008; Romero-Sandoval and Eisenach, 2007) . Systemically administered drugs may act at supraspinal, spinal, and peripheral sites, all of which are known to be involved in cannabinoid antinociception, and all of which contain CB1 receptors (Tsou et al., 1998; Walker and Huang, 2002) .
Significantly greater JWH015 effects were observed in females compared with males on the von Frey test of mechanical allodynia, in the persistent inflammatory pain model (study 2). We and others have reported that nonselective cannabinoid agonists such as THC and CP55940 are more potent in producing antinociception in female than in male rats (Tseng and Craft, 2001; Romero et al., 2002; Craft et al., 2012; Wakley et al., 2014a) , including in this inflammatory pain model (Craft et al., 2013) . However, in the present study, sex differences in JWH015-induced antinociception were observed only on one test, and only at 10 mg/kg. This dose also suppressed locomotor activity more in females than males (study 1), so it is possible that the sex difference in the antiallodynic effect of JWH015 is because of sex differences in its sedative effect. Given that the locomotor-suppressant effects of JWH015 were CB1 (and not CB2) receptormediated, the present results further suggest that sex differences in cannabinoid antinociception may be more likely to be observed with agonists that act at CB1 receptors, when drugs are administered systemically.
Sex differences in brain cannabinoid receptor mRNA or protein have been examined in a few studies, but appear to be highly region-dependent, and may also depend on the hormonal state of females (Castelli et al., 2014; Rodriguez de Fonseca et al., 1994; Xing et al., 2011) . In particular, greater cannabinoid receptor mRNA and protein has been found in female Sprague-Dawley rats compared with males in cerebellum (CB1) and in brainstem (CB2) (Xing et al., 2011) ; cannabinoid actions in these brain areas may contribute to their motoric and antinociceptive effects, respectively. We are not aware of any published studies comparing spinal or peripheral cannabinoid receptor density or function in female versus male rats, other than one study demonstrating greater CB1 versus CB2 receptor mediation of JWH015's antiallodynic effect against persistent inflammatory pain. Three days after intraplantar (i.pl.) hindpaw CFA injection, vehicle, rimonabant (1 mg/kg), or SR144528 (1 mg/kg) was injected intraperitoneal (i.p.); 30 min later vehicle or JWH015 (10 mg/kg) was injected i.p., and rats were tested for mechanical allodynia. Each point is the mean + SEM of eight rats/sex (vehicle or antagonist alone) or 12 rats/sex (JWH015-treated groups). *Significantly different from the same-sex, vehicle + vehicle group; + Significant antagonism compared with the same-sex, vehicle + JWH015 group, P ≤ 0.05.
CB1 receptor mRNA in the trigeminal ganglia of males compared with females when masseter muscle inflammation was induced by local CFA injection (Niu et al., 2012) . Thus, it remains to be determined to what extent sex differences in cannabinoid antinociception after systemic drug administration are explained by sex differences in CB1 and/or CB2 receptor pharmacology at supraspinal versus spinal versus peripheral levels.
We are aware of three published studies comparing cannabinoid analgesia in women versus men. In one study, nabilone decreased temporal summation of heat hyperalgesia in healthy, non-cannabis-using women but not men (Redmond et al., 2008) . In another study, conducted in healthy, daily cannabis users, dronabinol and smoked marijuana produced similar analgesic effects in women and men on the cold pressor test (Cooper et al., 2013) . A subsequent retrospective analysis revealed greater analgesia from smoked cannabis in men compared with women daily cannabis users (Cooper and Haney, 2016) . The extent to which participants were drug-tolerant in the latter two studies is not known; we have shown that female rats are more susceptible than males to the development of tolerance to THC-induced antinociception (Wakley et al., 2014b) , suggesting that sex differences in cannabinoid potency and efficacy can change with repeated use. Clearly, additional studies are needed to determine whether sex differences observed in rodent studies of cannabinoid antinociception are reliable and translatable to humans, and to determine whether results from human laboratory studies generalize to clinical pain populations, so as to clarify whether the analgesic potency and efficacy of cannabinoids, particularly CB2-preferring agonists, are the same in women and men.
Conclusion
Unlike nonselective cannabinoid agonists such as THC, which tend to be more potent in producing antinociception in female compared with male rats, the CB2-preferring agonist JWH015 produced similar antinociception in female and male rats on tests of acute pain and persistent inflammatory pain, despite being more potent in suppressing locomotor activity in females than in males. JWH015-induced antinociception was CB1 and CB2 receptor-mediated, whereas its locomotorsuppressant effect was CB1 receptor-mediated. Future studies examining a wider variety of cannabinoid agonists will be needed to determine whether sex differences in cannabinoid antinociception are consistent across drugs in this class, and whether they reflect sex differences in CB1 and/or CB2 receptor pharmacology.
